Predicting biotech is a humbling exercise, since a single trial readout can reorder an entire field overnight. But the forces shaping the next year are largely visible now, and understanding them is genuinely useful for anyone building, funding, or working in the industry. Here is what looks most likely to define biotech in 2027, offered with appropriate humility about how much can change.
The patent cliff drives everything
The single most powerful force in the industry is the wave of major drugs losing exclusivity over the coming years, which threatens an enormous amount of large-pharma revenue. This is not a prediction but an arithmetic certainty, and it explains a great deal of what is happening: the surge in acquisitions, the frantic in-licensing, the appetite for de-risked late-stage assets, and the willingness to pay large sums for the right programs. Expect this pressure to continue driving M&A and licensing activity, which is good news for biotechs with attractive assets and for the investors backing them, since it sustains the exit environment the whole ecosystem depends on.
Obesity keeps reshaping the industry
The metabolic boom shows no sign of exhausting itself. With oral drugs now on the market and next-generation combinations advancing, the category continues to expand, and its effects ripple outward: manufacturing capacity is strained, capital is drawn toward metabolic programs, and the drugs’ expanding benefits across cardiovascular, liver, and other conditions keep enlarging the addressable population. Watch for the next-generation readouts, the competitive response from challengers trying to break the duopoly, and the growing question of how health systems afford a therapy that a very large share of the population might benefit from.
The modalities to watch
Several technologies are at genuinely interesting inflection points. Targeted protein degradation crossed the threshold from promise to proven with its first approval, and the coming clinical data, especially outside oncology in immunology and neuroscience, will determine whether it becomes a broad new class. Radiopharmaceuticals continue their rapid ascent, with the shift toward more potent alpha emitters and a race to solve the isotope supply bottleneck that constrains the whole field. ADCs remain the hottest oncology category, with next-generation designs aiming to widen the therapeutic window. And cell and gene therapy continues to wrestle with the gap between remarkable clinical results and difficult commercial economics, a tension that must eventually resolve one way or the other.
AI moves from promise to proof
The AI story in drug discovery is entering a more consequential phase. The first approval of a PROTAC showed that a novel modality can travel from concept to medicine; the equivalent test for AI is whether drugs discovered or designed with machine learning succeed in the clinic at rates that justify the enormous investment. Expect scrutiny to intensify and the gap between substance and hype to become more visible as more AI-derived candidates produce human data. Meanwhile AI is quietly transforming the unglamorous parts of the industry, clinical operations, regulatory work, manufacturing, and data analysis, where the returns may prove larger and more certain than in discovery.
The financing and policy backdrop
Two structural forces bear watching. On capital, the selective reopening of the IPO window in 2026 raised the question of whether access broadens to earlier-stage companies or remains concentrated among de-risked, late-stage names. The answer will shape how easily the next generation of biotechs gets funded. On policy, Medicare price negotiation continues to expand, the debate over its effects on innovation remains unresolved, and the geopolitics around Chinese biotech, licensing, and manufacturing continues to reshape supply chains and partnering strategy. Neither of these is likely to be settled in 2027, but both will shape decisions throughout it.
What would change the picture
Honesty demands acknowledging the uncertainty. A major clinical failure in a hot area, a surprising approval, a sharp macroeconomic turn, or a significant policy shift could each reorder these expectations quickly. Biotech is a field where the base rates are brutal and the surprises are frequent, which is precisely why the industry’s collective attention swings so violently. Treat any outlook, including this one, as a framework for watching rather than a forecast to rely on.
The bottom line
Biotech in 2027 will be shaped above all by the patent cliff driving M&A and licensing, the continuing expansion of the obesity franchise, the maturation of protein degradation and radiopharmaceuticals, the moment of truth for AI-derived drugs, and an unresolved policy and financing environment. The through-line is an industry with real scientific momentum operating under significant commercial and political pressure. For those building companies, the practical implication is that de-risked assets in hot areas will find capital and partners, while everything else will need to work harder, which is a demanding but navigable environment.
What it means for people in the industry
Beyond the headline trends, it is worth translating the outlook into what it actually means for the people making decisions inside the industry. For founders and executives, the environment rewards de-risking and focus: capital and partners are available for programs with real clinical data in areas of strategic interest, and much harder to find for everything else, which argues for concentrating resources on reaching meaningful data rather than spreading thin across a broad pipeline. For investors, the M&A wave sustains the exit environment that makes the whole model work, but the concentration of capital around de-risked, late-stage assets means the returns are competitive and the early-stage risk is being priced carefully. For job seekers and employees, hiring follows the money, which means the strongest opportunities cluster in the functions that move drugs toward approval, regulatory, clinical, manufacturing, and in the therapeutic areas drawing investment, while areas out of favor remain difficult. For service providers, the manufacturing reshoring wave, the ADC and radiopharmaceutical booms, and the surge in dealmaking all create genuine demand, and the providers positioned in those currents will do well. And for everyone, the policy environment, on pricing, on China, on trade, has become something that must be actively tracked rather than assumed stable, because it is now a first-order determinant of strategy rather than background noise. The overarching picture is an industry with real scientific momentum, real commercial pressure, and an unusual amount of political and structural change running through it, which rewards those who pay attention and punishes those who assume the last decade’s rules still apply.
A closing caveat
Every outlook is a snapshot of expectations, and biotech has an unmatched capacity to make forecasters look foolish. A single unexpected readout, a surprising approval, a policy shift, or a macro turn can reorder the entire picture in a week. The value of thinking about the year ahead is not in the accuracy of the prediction but in the clarity it brings to what you are watching and why, so that when the surprises come, and they will, you understand what has actually changed and what it means for you. Hold these views lightly, watch the data as it lands, and be willing to update quickly, which is the only forecasting discipline that has ever worked in this industry.
The one thing worth watching most
If you track a single variable through 2027, make it the flow of capital: whether the IPO window broadens beyond de-risked late-stage names, whether venture funding reaches earlier-stage companies again, and whether the M&A wave sustains. Capital availability determines how many companies get founded, how many programs advance, how many people get hired, and how much science actually gets attempted. The scientific stories are more interesting, but the financing story is the one that determines whether the science gets funded at all, and it is therefore the leading indicator for almost everything else in the industry.
To follow these stories as they develop, the BioMed Nexus daily brief tracks them as they happen, and see our deeper pieces on the obesity gold rush, targeted protein degradation, and the M&A wave.
Frequently asked questions
What will drive biotech in 2027?
The dominant force is the patent cliff, as major drugs lose exclusivity and threaten enormous large-pharma revenue, which drives M&A and in-licensing. Other key forces are the continuing obesity boom, the maturation of modalities like targeted protein degradation and radiopharmaceuticals, the test of whether AI-derived drugs succeed clinically, and an unresolved policy and financing environment.
Which biotech modalities should I watch in 2027?
Targeted protein degradation, which crossed from promise to proven with its first approval and now faces clinical tests outside oncology; radiopharmaceuticals, ascending fast but constrained by isotope supply; antibody-drug conjugates, still the hottest oncology category with next-generation designs advancing; and cell and gene therapy, still wrestling with the gap between clinical results and commercial economics.
Is the biotech funding environment improving?
It improved selectively in 2026, with the IPO window reopening for de-risked, late-stage companies with strong data and experienced teams, alongside a surge in M&A that returns capital to investors. The open question is whether access broadens to earlier-stage and platform companies, which would shape how easily the next generation of biotechs gets funded.
